151 related articles for article (PubMed ID: 18724617)
1. Contemporary management of hepatocellular carcinoma.
Palmer D
Clin Med (Lond); 2008 Aug; 8(4):442-7. PubMed ID: 18724617
[No Abstract] [Full Text] [Related]
2. [Nonsurgical management of hepatocellular carcinoma].
Merle P; Mornex F
Cancer Radiother; 2010 Oct; 14(6-7):469-73. PubMed ID: 20739209
[TBL] [Abstract][Full Text] [Related]
3. Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era.
Pfiffer TE; Seehofer D; Nicolaou A; Neuhaus R; Riess H; Trappe RU
Tumori; 2011; 97(4):436-41. PubMed ID: 21989430
[TBL] [Abstract][Full Text] [Related]
4. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.
Burak KW; Thomas MB; Zhu AX
HPB (Oxford); 2010 Jun; 12(5):321-2. PubMed ID: 20590906
[No Abstract] [Full Text] [Related]
5. Hepatocellular carcinoma: sorafenib before liver transplantation?
Braillon A
Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
[No Abstract] [Full Text] [Related]
6. Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
Rowe IA
Hepatology; 2010 Sep; 52(3):1171-2. PubMed ID: 20812364
[No Abstract] [Full Text] [Related]
7. [Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers].
Varela M; Reig M; de la Mata M; Matilla A; Bustamante J; Pascual S; Turnes J; Aracil C; Del Val A; Pascasio JM; Rodríguez M; Bruix J
Med Clin (Barc); 2010 May; 134(13):569-76. PubMed ID: 20036398
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.
Zhu AX
Clin Drug Investig; 2012 Aug; 32 Suppl 2():1-2. PubMed ID: 22873622
[No Abstract] [Full Text] [Related]
9. Management of hepatocellular carcinoma: an update.
Bruix J; Sherman M;
Hepatology; 2011 Mar; 53(3):1020-2. PubMed ID: 21374666
[No Abstract] [Full Text] [Related]
10. Sorafenib, a systemic therapy for hepatocellular carcinoma.
Méndez-Sánchez N; Vásquez-Fernández F; Zamora-Valdés D; Uribe M
Ann Hepatol; 2008; 7(1):46-51. PubMed ID: 18376365
[TBL] [Abstract][Full Text] [Related]
11. Review article: the management of hepatocellular carcinoma.
Cabrera R; Nelson DR
Aliment Pharmacol Ther; 2010 Feb; 31(4):461-76. PubMed ID: 19925500
[TBL] [Abstract][Full Text] [Related]
12. Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes.
Ramanathan R; Sharma A; Lee DD; Behnke M; Bornstein K; Stravitz RT; Sydnor M; Fulcher A; Cotterell A; Posner MP; Fisher RA
Transplantation; 2014 Jul; 98(1):100-6. PubMed ID: 24503764
[TBL] [Abstract][Full Text] [Related]
13. Current management of hepatocellular carcinoma.
Mendizabal M; Reddy KR
Med Clin North Am; 2009 Jul; 93(4):885-900, viii. PubMed ID: 19577120
[TBL] [Abstract][Full Text] [Related]
14. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P
BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146
[TBL] [Abstract][Full Text] [Related]
15. Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.
Sinakos E; Dedes I; Papalavrentios L; Drevelegas A; Akriviadis E
Scand J Gastroenterol; 2010 Apr; 45(4):511-2. PubMed ID: 20113152
[No Abstract] [Full Text] [Related]
16. Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma.
Vitale A; Lombardi G; Ramirez Morales R; Cillo U
Dig Liver Dis; 2012 May; 44(5):361-2. PubMed ID: 22424640
[No Abstract] [Full Text] [Related]
17. Major achievements in hepatocellular carcinoma.
Bruix J; Llovet JM
Lancet; 2009 Feb; 373(9664):614-6. PubMed ID: 19231618
[No Abstract] [Full Text] [Related]
18. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation.
TAN WF; Qiu ZQ; YU Y; RAN RZ; YI B; LAU WY; LIU C; QIU YH; FENG FL; WANG JH; YAN PN; ZHANG BH; WU MC; LUO XJ; JIANG XQ
Acta Pharmacol Sin; 2010 Dec; 31(12):1643-8. PubMed ID: 21102481
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib-induced destructive thyroiditis.
Iavarone M; Perrino M; Viganò M; Beck-Peccoz P; Fugazzola L
Thyroid; 2010 Sep; 20(9):1043-4. PubMed ID: 20825302
[No Abstract] [Full Text] [Related]
20. TACE with or without systemic therapy?
Dufour JF
J Hepatol; 2012 Jun; 56(6):1224-5. PubMed ID: 22402292
[No Abstract] [Full Text] [Related]
[Next] [New Search]